Targeting Tumor Microenvironment by Small-Molecule Inhibitors
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The tumor microenvironment (TME) is a hypoxic, acidic, and immune/inflammatory cell-enriched milieu that plays crucial roles in tumor development, growth, progression, and therapy resistance. Targeting TME is an attractive strategy for the treatment of solid tumors. Conventional cancer chemotherapies are mostly designed to directly kill cancer cells, and the effectiveness is always compromised by their penetration and accessibility to cancer cells. Small-molecule inhibitors, which exhibit good penetration and accessibility, are widely studied, and many of them have been successfully applied in clinics for cancer treatment. As TME is more penetrable and accessible than tumor cells, a lot of efforts have recently been made to generate small-molecule inhibitors that specifically target TME or the components of TME or develop special drug-delivery systems that release the cytotoxic drugs specifically in TME. In this review, we briefly summarize the recent advances of small-molecule inhibitors that target TME for the tumor treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Macrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Therefore, some therapeutic strategies are designed to normalize tumor vasculature, which can alleviate hypoxia in tumor and increase the efficacy of therapies [127].”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“For instance, the subset of CD4þCD25þFOXP3þ regulatory T (Treg) cells suppress tumor-specific T-cell immunity and are associated with poor prognosis in ovarian carcinoma [97], and tumor-infiltrating CD4þCD25þFOXP3þ Treg cells showed prometastatic function in receptor activator of nuclear factor-kB (RANK)-expressing br…”
BackgroundHow Matrix Metalloproteinases Regulate Cell Behavior
Sternlicht, M. D., & Werb, Z. (2001) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.17.1.463 · Cited by 3,959
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
The Extracellular Matrix: Not Just Pretty Fibrils
Hynes, R. O. (2009) · Science · doi:10.1126/science.1176009 · Cited by 3,527
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Arginine metabolism: nitric oxide and beyond
WU, G., & MORRIS, S. M. (1998) · Biochemical Journal · doi:10.1042/bj3360001 · Cited by 2,811
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
Hockel, M., & Vaupel, P. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.266 · Cited by 2,662
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
Hyaluronan: from extracellular glue to pericellular cue
Toole, B. P. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1391 · Cited by 2,125
Cox, T. R., & Erler, J. T. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.004077 · Cited by 1,569
Hypoxia and the extracellular matrix: drivers of tumour metastasis
Gilkes, D. M., Semenza, G. L., & Wirtz, D. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3726 · Cited by 1,520 · cited 3×
“TME is an essential part of the tumor mass, which is important for tumor growth, progression, metastasis, and therapy resistance [4,6,8].”
BackgroundRole of tumor microenvironment in tumorigenesis
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17648 · Cited by 1,404 · cited 1×
“TME is an essential part of the tumor mass, which is important for tumor growth, progression, metastasis, and therapy resistance [4,6,8].”
BackgroundNaba, A., Clauser, K. R., Hoersch, S., Liu, H., Carr, S. A., & Hynes, R. O. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014647 · Cited by 1,354
Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma
Steidl, C., Lee, T., Shah, S. P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S. J., Iqbal, J., Weisenburger, D. D., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905680 · Cited by 1,262 · cited 1×
“A high presence of TAMs in TME is significantly associated with poor prognosis of patients [77,78].”
BackgroundFolkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Hypoxia, DNA repair and genetic instability
Bristow, R. G., & Hill, R. P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2344 · Cited by 1,140 · cited 1×
“microenvironment; ECM, extracellular matrix; EPR, enhanced per metabolism, erythropoietin (EPO) production, deregulating DNA repair systems, recruiting the stromal components, as well as upregulating protooncogenes and hypoxia-inducible factor (HIF) 1a and HIF 2a [18,19].”
BackgroundHyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
The extracellular matrix: tools and insights for the "omics" era
Naba, A., Clauser, K. R., Ding, H., Whittaker, C. A., Carr, S. A., & Hynes, R. O. (2016) · Matrix Biology · doi:10.1016/j.matbio.2015.06.003 · Cited by 1,037
Biology of the Extracellular Matrix: An Overview
Yue, B. (2014) · Journal of Glaucoma · doi:10.1097/ijg.0000000000000108 · Cited by 805
Cancer associated fibroblasts (CAFs) in tumor microenvironment
Xing, F. (2010) · Frontiers in Bioscience · doi:10.2741/3613 · Cited by 682
Tumor hypoxia and malignant progression
Vaupel, P., Mayer, A., & Höckel, M. (2004) · Methods in Enzymology · doi:10.1016/s0076-6879(04)81023-1 · Cited by 496 · cited 2×
“The disorganized vascular networks in tumor site that induce diffusion distance of oxygen also contribute to low oxygen level in TME [6,14,15].”
BackgroundEffect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs
Luciani, F., Spada, M., De Milito, A., Molinari, A., Rivoltini, L., Montinaro, A., Marra, M., Lugini, L., Logozzi, M., Lozupone, F., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh305 · Cited by 435
Dudley, A. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006536 · Cited by 424 · cited 1×
“The tumor vessels are disorganized, irregular, fragile, and leaky, resulting in abnormal blood flow in tumor [126].”
BackgroundMacrophage Responses to Hypoxia
Lewis, C., & Murdoch, C. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62038-x · Cited by 413
Cancer associated fibroblasts: An essential role in the tumor microenvironment
Tao, L., Huang, G., Song, H., Chen, Y., & Chen, L. (2017) · Oncology Letters · doi:10.3892/ol.2017.6497 · Cited by 351
Cohen, Z. R., Ramishetti, S., Peshes-Yaloz, N., Goldsmith, M., Wohl, A., Zibly, Z., & Peer, D. (2015) · ACS Nano · doi:10.1021/nn506248s · Cited by 182
Cited by
The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research
Pinto, B., Henriques, A. C., Silva, P. M. A., & Bousbaa, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121186 · Cited by 440
“The TME imposes many biological barriers that greatly hinder drug delivery to tumors [39,40].”
BackgroundTumor microenvironment: barrier or opportunity towards effective cancer therapy
Tiwari, A., Trivedi, R., & Lin, S.-Y. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00866-3 · Cited by 377
Small Molecules against Metastatic Tumors: Concrete Perspectives and Shattered Dreams
Serra, M., Rubes, D., Schinelli, S., & Paolillo, M. (2023) · Cancers · doi:10.3390/cancers15164173 · Cited by 13
Metadata
- Authors
- Zhong, S., Jeong, J.-H., Chen, Z., Chen, Z., & Luo, J.-L.
- Venue
- Translational Oncology
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 13
- Issue
- 1
- Pages
- 57-69
- ISSN
- 1936-5233 (ISSN-L)
- OpenAlex
- W2989955476
- Cited by
- 134
- References
- 32
- FWCI
- 4.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.